• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway

Opinion
Video

The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.

Video content above is prompted by the following question:

  • How do financial considerations influence your treatment decision-making process?
Related Videos
Frederick L Locke, MD, Moffitt
Pierluigi Porcu, MD
Andrew Kuykendall, MD
Andrew Kuykendall, MD, Moffitt Cancer Center
Related Content
While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com

Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 18th 2025
Article

Previous work had suggested pausing Bruton tyrosine kinase (BTK) inhibitors before COVID-19 vaccination might boost immunity in patients with chronic lymphocytic leukemia (CLL).

Read More

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

Managed Care Cast Presents: Challenges of Diagnosing and Managing PNH

July 16th 2024
Podcast

A trio of experts discuss the challenges of diagnosing and managing paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening disorder.

Listen

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com

Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025
Article

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Read More

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

September 15th 2018
Podcast

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Listen

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

April 10th 2025
Article

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

Read More

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com

Immune Microenvironment a Key Target in CLL

April 8th 2025
Article

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.